As New Rules Take Hold, What Does ‘Good AI Practice’ Look Like in Drug Development?

Key Takeaways

• EMA and FDA released joint AI good practice principles on Jan 14 2026.
• Principles require defined context of use, risk‑based controls, and documentation.
• Embedding AI within regulated workflows simplifies auditability versus standalone tools.
• Lifecycle management must cover models, prompts, data, and version control.
• Companies must map AI use cases to risk and enforce human oversight.

Pulse Analysis

The EMA‑FDA joint principles mark a watershed moment for artificial intelligence in pharmaceutical research. By establishing a shared, technology‑neutral baseline, regulators are moving the conversation from speculative capability to concrete operational expectations. The emphasis on "context of use" forces sponsors to evaluate AI not in isolation but as a functional element that can alter risk profiles, demanding clear documentation, human‑in‑the‑loop safeguards, and traceable decision pathways. This alignment reduces cross‑border regulatory friction and provides a clearer roadmap for compliance as AI becomes integral to clinical trial design, safety monitoring, and regulatory submissions.

Embedding AI directly into regulated systems, rather than treating it as an auxiliary tool, delivers immediate compliance benefits. Integrated solutions inherit existing role‑based permissions, audit trails, and change‑control mechanisms, turning AI outputs into auditable evidence rather than orphaned data streams. Effective lifecycle management now extends beyond model versioning to include prompts, data sources, and agent instructions, with continuous monitoring for drift and predefined risk‑based triggers. Organizations must institutionalize version control that captures every artefact influencing AI decisions, ensuring that any modification—whether a model update or a prompt tweak—undergoes proportional review and documentation.

For leaders, the operational shift presents a strategic advantage. By mapping AI use cases to risk tiers and embedding them within GxP‑compliant workflows, companies can scale AI initiatives without repeatedly reopening governance debates. Vendors are being pressed to demonstrate where AI sits in the workflow, how it integrates with electronic records, and how changes are auditable. With the EU AI Act becoming fully enforceable in August 2026 and the FDA’s 2024 guidance on electronic records already in effect, firms that adopt these principles now will not only meet regulatory expectations but also unlock faster, more reliable evidence generation—turning AI investment into a competitive edge.